NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy
IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation to treat primary generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…
Read More
NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients’ Seizure Burden
New Online Physician Portal Integrates RNS System’s EEG Data with Patient Seizure Diary App to Help Doctors Provide More Comprehensive, Data-Driven Care for Epilepsy Patients…
Read More
NeuroPace Awarded Five-Year NIH Grant Funding of More than $9M to Study RNS System in Patients with Lennox-Gastaut Syndrome
Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif. — June 30, 2021…
Read More
NeuroPace Receives FDA Breakthrough Device Designation for RNS System for Idiopathic Generalized Epilepsy
Company plans to pursue indication expansion to broaden access to include patients with second most common type of epilepsy. MOUNTAIN VIEW, Calif. – March 31,…
Read More
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy
Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif. – August 31, 2020 – NeuroPace,…
Read More
New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life
Personalized, data-driven treatment for refractory focal epilepsy demonstrates unprecedented real-world results and exceptional long-term clinical data MOUNTAIN VIEW, Calif. – July 27, 2020 – NeuroPace,…
Read More
NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment
Full-body MRI opens up valuable medical imaging possibilities for RNS System patients MOUNTAIN VIEW, Calif. – March. 9, 2020 – NeuroPace, Inc., a Silicon Valley-based…
Read More
New Data Presented at the American Epilepsy Society Annual Meeting Demonstrate Unprecedented Efficacy Outcomes with the NeuroPace RNS System
Real-world experience with the RNS System reveals best outcomes to date of any neuromodulation device for focal seizures MOUNTAIN VIEW, Calif. — December 9, 2019…
Read More
NeuroPace Appoints Mark Saxton as Vice President of Sales
Industry veteran to drive business development, strategy and enhance customer experience MOUNTAIN VIEW, Calif. — July 30, 2019 – NeuroPace, Inc., a Silicon Valley-based medical…
Read More
NeuroPace Announces Michael Favet as CEO
Frank Fischer appointed Chairman of Board of Directors MOUNTAIN VIEW, Calif. - July 24, 2019 (BUSINESS WIRE)--NeuroPace, Inc., a Silicon Valley-based medical technology company, today…
Read More
NIH Study to Utilize NeuroPace RNS® System for Research on the Brain’s Reward System
Study Aims to Assess Whether Closed-Loop Neuromodulation Could Help Manage
Medically Refractory Obesity MOUNTAIN VIEW, Calif. — July 10, 2019 – NeuroPace, Inc., a Silicon…
Read More
NeuroPace Shares Positive Data from Studies of the RNS System at the American Academy of Neurology 2019 Annual Meeting
Results Demonstrate Significant Seizure Reduction in Adults with Drug-Resistant Epilepsy; Insights into the Human Brain MOUNTAIN VIEW, Calif. — May 9, 2019 – NeuroPace, Inc.,…
Read More
NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain Neurostimulator
Supports Value of Insights Provided by Brain Recordings from the NeuroPace RNS® System for Drug-Resistant Epilepsy MOUNTAIN VIEW, Calif. – February 12, 2019 – NeuroPace, Inc., a…
Read More
NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting
More than One-Third of Drug-Resistant Epilepsy Patients Achieved ≥90% Seizure Reduction with the RNS System. NEW ORLEANS--(BUSINESS WIRE)--American Epilepsy Society Annual Meeting, Booth 519 —…
Read More
